Clinical Trial Update: ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating ZEN003694 in combination with enzalutamide versus enzalutamide monotherapy in metastatic castration-resistant prostate can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• ZEN003694

Snippet

Sponsor: Zenith Epigenetics | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: RECRUITING